Selected article for: "ARDS group and significant difference"
Author: Xie, Yun; Cao, Song; Dong, Hui; Lv, Hui; Teng, Xiaolei; Zhang, Jiaxiang; Wang, Tao; Zhang, Xiaoyan; Qin, Yun; Chai, Yujing; Yang, Luyu; Liu, Jun; Wang, Ruilan
Title: Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation
  • Cord-id: at99z1cp
  • Document date: 2021_9_15
    • ID: at99z1cp
    Snippet: BACKGROUND: Our goal is to further elucidate the clinical condition and prognosis of patients with severe acute COVID-19 with EBV reactivation. METHOD: This is a retrospective single-center study of COVID-19 patients admitted to the intensive care unit of Wuhan No. 3 Hospital (January 31 to March 27, 2020). According to whether Epstein-Barr virus reactivation was detected, the patients were divided into an EBV group and a Non-EBV group. Baseline data were collected including epidemiological, lar
    Document: BACKGROUND: Our goal is to further elucidate the clinical condition and prognosis of patients with severe acute COVID-19 with EBV reactivation. METHOD: This is a retrospective single-center study of COVID-19 patients admitted to the intensive care unit of Wuhan No. 3 Hospital (January 31 to March 27, 2020). According to whether Epstein-Barr virus reactivation was detected, the patients were divided into an EBV group and a Non-EBV group. Baseline data were collected including epidemiological, larithmics, clinical and imaging characteristics, and laboratory examination data. RESULTS: Of the 128 patients with COVID-19, 17 (13.3%) were infected with Epstein-Barr virus reactivation. In the symptoms,the rate of tachypnoea in the EBV group was apparently higher than that in the Non-EBV group. In lab tests, the lymphocyte and albumin of EBV group decreased more significantly than Non-EBV group, and the D-dimer and serum calcium of EBV group was higher than Non-EBV group. Regarding the infection index, CRP of EBV group was apparently above the Non-EBV group, and no significant difference was found in procalcitonin of the two groups. The incidence of respiratory failure, ARDS, and hypoproteinaemia of EBV group had more incidence than Non-EBV group. The 28-day and 14-day mortality rates of EBV group was significantly higher than that of Non-EBV group. CONCLUSIONS: In the COVID-19 patients, patients with EBV reactivation had higher 28-day and 14-day mortality rates and received more immuno-supportive treatment than patients of Non-EBV group.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest and acute kidney injury: 1, 2, 3
    • abnormal chest and acute liver: 1
    • abnormal chest and acute myocardial: 1
    • abnormal chest and acute myocardial injury: 1
    • abnormal chest and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • abnormal chest and acute respiratory distress syndrome respiratory failure: 1, 2
    • abnormal chest and acute stage: 1
    • abnormal chest and liver function: 1, 2
    • abnormal chest and low albumin: 1, 2
    • abnormal chest and low lymphocyte: 1, 2
    • abnormal chest and lymph cell: 1
    • abnormal chest and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • abnormal liver function and acute kidney injury: 1, 2, 3, 4
    • abnormal liver function and acute liver: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abnormal liver function and acute liver injury: 1, 2, 3, 4, 5, 6
    • abnormal liver function and acute respiratory distress syndrome: 1
    • abnormal liver function and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • abnormal liver function and low albumin: 1
    • abnormal liver function and low lymphocyte: 1, 2